With La Jolla's $500M Giapreza nod, FDA breaks a high-water mark for approvals
admin 22nd December 2017 Uncategorised 0The latest drugmaker to benefit from the FDA’s year-end sprint is La Jolla Pharmaceutical, which picked up its first-ever drug approval—and the agency’s 46th of the year. Giapreza, a treatment for dangerously low blood pressure, is expected to hit $500 million at peak.
More: With La Jolla's 0M Giapreza nod, FDA breaks a high-water mark for approvals
Source: fierce